SAB Biotherapeutics, Inc.

Informe acción NasdaqCM:SABS

Capitalización de mercado: US$27.1m

SAB Biotherapeutics Dirección

Dirección controles de criterios 4/4

El CEO de SAB Biotherapeutics' es Samuel Reich , nombrado en Jan 2024, tiene una permanencia de menos de un año. compensación anual total es $768.40K, compuesta por 45.5% salario y 54.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.24% de las acciones de la empresa, por valor de $71.18K. La antigüedad media del equipo directivo y de la junta directiva es de 2 años y 4 años, respectivamente.

Información clave

Samuel Reich

Chief Executive Officer (CEO)

US$768.4k

Compensación total

Porcentaje del salario del CEO45.5%
Permanencia del CEOless than a year
Participación del CEO0.2%
Permanencia media de la dirección2yrs
Promedio de permanencia en la Junta Directiva4yrs

Actualizaciones recientes de la dirección

Recent updates

Improved Revenues Required Before SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock's 42% Jump Looks Justified

Apr 17
Improved Revenues Required Before SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock's 42% Jump Looks Justified

Analysts Are Betting On SAB Biotherapeutics, Inc. (NASDAQ:SABS) With A Big Upgrade This Week

Jan 20
Analysts Are Betting On SAB Biotherapeutics, Inc. (NASDAQ:SABS) With A Big Upgrade This Week

Need To Know: Analysts Are Much More Bullish On SAB Biotherapeutics, Inc. (NASDAQ:SABS) Revenues

Nov 19
Need To Know: Analysts Are Much More Bullish On SAB Biotherapeutics, Inc. (NASDAQ:SABS) Revenues

Earnings Beat: SAB Biotherapeutics, Inc. (NASDAQ:SABS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Nov 18
Earnings Beat: SAB Biotherapeutics, Inc. (NASDAQ:SABS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

SAB Bio rises as H1N1 influenza and COVID-19 treatments show efficacy in trial

Sep 28

What Does The Future Hold For SAB Biotherapeutics, Inc. (NASDAQ:SABS)? These Analysts Have Been Cutting Their Estimates

Aug 12
What Does The Future Hold For SAB Biotherapeutics, Inc. (NASDAQ:SABS)? These Analysts Have Been Cutting Their Estimates

SAB Biotherapeutics GAAP EPS of -$0.11 beats by $0.03

Aug 10

Downgrade: Here's How Analysts See SAB Biotherapeutics, Inc. (NASDAQ:SABS) Performing In The Near Term

Apr 06
Downgrade: Here's How Analysts See SAB Biotherapeutics, Inc. (NASDAQ:SABS) Performing In The Near Term

SAB Biotherapeutics: Advancing A New Class Of Immunotherapies Leveraging Polyclonal Antibodies

Dec 02

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Samuel Reich en comparación con los beneficios de SAB Biotherapeutics?
FechaCompensación totalSalarioIngresos de la empresa
Mar 31 2024n/an/a

-US$40m

Dec 31 2023US$768kUS$350k

-US$42m

Sep 30 2023n/an/a

-US$27m

Jun 30 2023n/an/a

-US$29m

Mar 31 2023n/an/a

-US$27m

Dec 31 2022US$985kUS$350k

-US$19m

Sep 30 2022n/an/a

-US$22m

Jun 30 2022n/an/a

-US$19m

Mar 31 2022n/an/a

-US$18m

Dec 31 2021US$3mUS$53k

-US$17m

Compensación vs. Mercado: La compensación total ($USD768.40K) de Samuel está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD673.68K).

Compensación vs. Ingresos: La compensación de Samuel ha sido consistente con los resultados de la empresa en el último año.


CEO

Samuel Reich (49 yo)

less than a year

Permanencia

US$768,396

Compensación

Mr. Samuel J. Reich is CEO of SAB Biotherapeutics, Inc. from January 30, 2024 and serves as its Executive Chairman since October 22, 2021 and serves as its Director since November 2020. Samuel J. Reich has...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Samuel Reich
CEO & Executive Chairmanless than a yearUS$768.40k0.24%
$ 64.4k
Eddie Sullivan
Co-Founder10.4yrsUS$807.76k5.67%
$ 1.5m
Christine Hamilton
Co-Founder & Independent Directorno dataUS$25.00k5.63%
$ 1.5m
Christoph Bausch
Executive VP & COO2.1yrsUS$549.32k1.08%
$ 293.2k
Alexandra Kropotova
Executive VP & Chief Medical Officer2yrsUS$921.58k0%
$ 0
Edward Hamilton
Co-Founder & Board Observerno datasin datos3.15%
$ 855.2k
Mark Conley
Interim Chief Financial Officerno datasin datossin datos
Carlos Carillo
Senior Vice President of Regulatory Affairs3yrssin datossin datos

2.0yrs

Permanencia media

53yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de SABS se considera experimentado (2 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Samuel Reich
CEO & Executive Chairman3.6yrsUS$768.40k0.24%
$ 64.4k
Eddie Sullivan
Co-Founderno dataUS$807.76k5.67%
$ 1.5m
Christine Hamilton
Co-Founder & Independent Director10.4yrsUS$25.00k5.63%
$ 1.5m
Edward Hamilton
Co-Founder & Board Observer2.7yrssin datos3.15%
$ 855.2k
William Polvino
Independent Director5.4yrsUS$25.00k0%
$ 0
Jeffrey Spragens
Independent Director3.6yrsUS$25.00k0.43%
$ 116.1k
David Link
Independent Vice Chairman6.4yrsUS$25.00k0.062%
$ 16.9k
Erick Lucera
Independent Director1.2yrsUS$26.93k0%
$ 0
Jim Robl
Member of Scientific Advisory Boardno datasin datossin datos
Arturo Casadevall
Member of Scientific Advisory Boardno datasin datossin datos
Michael Haller
Member of Scientific Advisory Boardno datasin datossin datos
Stephen Gitelman
Member of Scientific Advisory Board4.4yrssin datossin datos

4.0yrs

Permanencia media

64yo

Promedio de edad

Junta con experiencia: La junta directiva de SABS se considera experimentada (4 años de antigüedad promedio).